Olema Shorts Stay Elevated as Pipeline Verdict Looms
OLMA heads into the autumn with one of the most heavily shorted profiles in clinical-stage biotech and a stock that has lost nearly 5% in a week, testing bulls whose conviction rests entirely on a single Phase 3…